SCHEMBL37545

SCHEMBL37545

O=S(=O)(O)CCCCOCCCCS(=O)(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.48
LMNA P02545 4/20 0.39
BLM P54132 2/20 0.39
PTGS1 P23219 1/20 0.39
PDE4A P27815 1/20 0.39
SLC6A6 P31641 1/20 0.39
CYP2C19 P33261 1/20 0.39
ALDH1A1 P00352 3/20 0.33
POLB P06746 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALOX15 P16050 2/20 0.33
KDM4E B2RXH2 2/20 0.33
MAPT P10636 2/20 0.33
HTT P42858 2/20 0.33
NPC1 O15118 1/20 0.33
BRCA1 P38398 1/20 0.33
GMNN O75496 1/20 0.33
PKM P14618 1/20 0.33
THPO P40225 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL754168 0.97 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL18380848 0.97 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL420986 0.97 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL312671 0.97 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL30782568 0.97 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL419968 0.97 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL754172 0.97 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL30133577 0.97 APP (0.46) APPLMNABLMPTGS1PDE4A
Bromide SCHEMBL31659017 0.97 APP (0.46) APPLMNABLMPTGS1PDE4A
SCHEMBL193290 0.97 APP (0.46) APPLMNABLMPTGS1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7236 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130856-A1 LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF NANOTECH PHARMA INC (US) 2026-05-14 US claimed
US-20260124148-A1 POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY BHAMIS RES LABORATORY PVT LTD (IN) 2026-05-07 US claimed
US-12616694-B2 Pharmaceutical compositions for subcutaneous administration of levosimendan TENAX THERAPEUTICS, INC. (US) 2026-05-05 US claimed
WO-2026089751-A1 COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS Finitus, LLC (US) 2026-04-30 WO claimed
WO-2026089754-A1 COMPOSITIONS AND METHODS FOR INTRANASAL DELIVERY OF THERAPEUTIC PEPTIDES Finitus, LLC (US) 2026-04-30 WO claimed
WO-2026089752-A1 COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF THERAPEUTIC PEPTIDES Finitus, LLC (US) 2026-04-30 WO claimed
EP-4678649-A1 USE OF SUBSTITUTED CYCLODEXTRIN FOR VIRAL INACTIVATION IN BIOMANUFACTURING ROQUETTE FRERES (FR) 2026-01-14 EP claimed
EP-4674409-A1 ORAL TABLETS FOR THE COLONIC DELIVERY OF THERAPEUTIC PROTEINS ROQUETTE FRERES (FR) 2026-01-07 EP claimed
US-20250367121-A1 DOSAGE FORMS COMPRISING ACTIVE PHARMACEUTICAL INGREDIENTS AXSOME THERAPEUTICS INC (US) 2025-12-04 US claimed
US-12472255-B2 Pharmaceutical compositions comprising meloxicam AXSOME THERAPEUTICS, INC. (US) 2025-11-18 US claimed
US-6294192-B1 PHARMACEUTICAL COMPOSITIONS CAPABLE OF SOLUBILIZING THERAPEUTICALLY EFFECTIVE AMOUNTS OF HYDROPHOBIC THERAPEUTIC AGENTS. CARRIER INCLUDES A HYDROPHILIC SURFACTANT AND A HYDROPHOBIC SURFACTANT, AQUEOUS DISPERSION LIPOCINE, INC. 2001-09-25 US claimed
US-6267985-B1 COMPOSITION COMPRISING TRIGLYCERIDE, CARRIER COMPRISING AT LEAST TWO SURFACTANTS, AT LEAST ONE BEING HYDROPHILIC, THERAPEUTIC AGENT CAPABLE OF BEING SOLUBILIZED IN TRIGLYCERIDE AND/OR CARRIER; FORMS CLEAR AQUEOUS DISPERSION LIPOCINE INC. 2001-07-31 US claimed
EP-1117442-A1 DRY POWDER ACTIVE AGENT PULMONARY DELIVERY Inhale Therapeutic Systems, Inc. (US) 2001-07-25 EP claimed
WO-2001019339-A1 FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE AND SULFOALKYL ETHER CYCLODEXTRINS PHARMACIA ITALIA S.P.A. (IT) 2001-03-22 WO claimed
WO-2001019338-A1 FORMULATIONS FOR PARENTERAL USE OF ESTRAMUSTINE PHOSPHATE WITH IMPROVED PHARMACOLOGICAL PROPERTIES PHARMACIA ITALIA S.P.A. (IT) 2001-03-22 WO claimed
EP-1067942-A1 HIGH-ENERGY CYCLODEXTRIN COMPLEXES Cyclops, EHF. (IS) 2001-01-17 EP claimed
WO-2001001960-A1 CLEAR OIL-CONTAINING PHARMACEUTICAL COMPOSITIONS LIPOCINE, INC. (US) 2001-01-11 WO claimed
WO-2000050007-A1 COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF HYDROPHOBIC THERAPEUTIC AGENTS LIPOCINE, INC. (US) 2000-08-31 WO claimed
WO-2000015262-A1 DRY POWDER ACTIVE AGENT PULMONARY DELIVERY INHALE THERAPEUTIC SYSTEMS, INC. (US) 2000-03-23 WO claimed
WO-1999042111-A1 HIGH-ENERGY CYCLODEXTRIN COMPLEXES CYCLOPS, EHF. (IS) 1999-08-26 WO claimed